The influence of a new prostaglandin E2 analogue (FCE 20700) on gastric acid and pepsin secretion in the dog.
The effects of FCE 20700, a new prostaglandin E2 analogue, on gastric acid and pepsin secretion stimulated by different secretagogues were studied in dogs. Intravenous FCE 20700 produced a significant inhibition of total acid output (TAO) induced by pentagastrin or histamine in gastric fistula (GF) dogs. This effect was short-lasting and mainly due to a reduction in the volume of gastric juice with little acid concentration change. TAO and pepsin output stimulated by 2-deoxy-D-glucose were similarly inhibited by intravenous FCE 20700. In dogs chronically fitted with both GF and Heidenhain pouch (HP), intragastric FCE 20700 significantly inhibited TAO stimulated by pentagastrin or histamine from HP, while acid secretion from GF was not significantly affected. It is concluded that FCE 20700 possesses a weak antisecretory activity in dogs. Consequently the antiulcer effects of this prostaglandin derivative seem to be largely independent from its influence on gastric acid and pepsin secretion.
D000818:Animals; D003847:Deoxyglucose / Q000494:pharmacology; D015232:Dinoprostone / Q000031:analogs & derivatives*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D005747:Gastric Fistula / Q000378:metabolism; D005753:Gastric Mucosa / Q000187:drug effects; D006632:Histamine / Q000494:pharmacology; D010434:Pepsin A / Q000378:metabolism*; D011459:Prostaglandins E, Synthetic / Q000494:pharmacology*
D011459:Prostaglandins E, Synthetic; D006632:Histamine; C040808:FCE 20700; D003847:Deoxyglucose; D010434:Pepsin A; D015232:Dinoprostone